Pyxis Oncology (NASDAQ:PYXS) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Pyxis Oncology (NASDAQ:PYXS) from a hold rating to a sell rating in a research report report published on Sunday morning.

Other equities analysts have also issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Tuesday, March 24th. Royal Bank Of Canada dropped their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th. Stifel Nicolaus dropped their price target on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pyxis Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Pyxis Oncology Trading Up 0.7%

Pyxis Oncology stock opened at $1.46 on Friday. The firm has a market capitalization of $91.73 million, a P/E ratio of -1.13 and a beta of 1.41. The stock has a fifty day moving average price of $1.46 and a 200 day moving average price of $2.47. Pyxis Oncology has a 52 week low of $0.86 and a 52 week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Monday, March 23rd. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter, compared to analyst estimates of $0.13 million. As a group, equities analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in PYXS. Bank of America Corp DE increased its stake in Pyxis Oncology by 20.3% during the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after acquiring an additional 9,062 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Pyxis Oncology in the first quarter valued at about $81,000. XTX Topco Ltd acquired a new stake in shares of Pyxis Oncology in the second quarter valued at about $40,000. Marshall Wace LLP acquired a new stake in shares of Pyxis Oncology in the second quarter valued at about $163,000. Finally, Qube Research & Technologies Ltd grew its stake in shares of Pyxis Oncology by 128.4% in the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock valued at $113,000 after buying an additional 57,935 shares in the last quarter. 39.07% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.